Clinical Drug Experience Knowledgebase

Criteria

Inclusion Criteria:

Must be outpatient, not hospitalized
Male Patient between ages 50-80, inclusive
Histologically/Cytologically graded adenocarcinoma of the prostate
Must have T1, T2 or T3a adenocarcinoma of the prostate
Must be a candidate for radiation therapy. Hormone refractory patients excluded
WHO/ECOG score of 0,1 or 2

Exclusion Criteria:

NO evidence of urinary tract that would put the patient at risk in the opinion of the Investigator.

Used the following treatments for prostate Cancer

*immunotherapy *chemotherapy *External Beam Radiation *brachytherapy *hormonal therapy *biological response modifiers

Prior Prostate Surgery (excluding TUNA or TURP)
Undergone Orchiectomy, adrenalectomy, hypophysectomy or be receiving any product which could alter the function of these organs
Use of Investigational Drug, Biologic or device within five half-lives of its physiological action or three months prior to base line, whichever is longer
Over the counter or alternative medical therapies which have estrogenic or anti-androgenic effect
uncontrolled CHF within 6 months to baseline
Myocardial Infarct, coronary vascular procedure or Clinically SignificantCardiovascualr Disease within 6 months of baseline Visit
Venous thrombosis with in 6 Months of Screening
Uncontrolled Hypertension defined as >170/100 or Symptomatic Hypotension within 3 months of Baseline
Insulin dependant Diabetic Patients Must not administer in an anatomic region where they will receive Eligard.
Drug or Alcohol Abuse 6 months prior to Baseline
Other Serious Illness at the discretion of the Investigator
Patients receiving anti-coagulant or anti-platlet medication must be on a stable dose for 3 months prior to Baseline
Hypersensitivity to GnRH, GnRH agonists